key: cord-0779622-9iez9uwv
authors: Zhu, Hanzhao; Zhang, Liyun; Ma, Yubo; Zhai, Mengen; Xia, Lin; Liu, Jincheng; Yu, Shiqiang; Duan, Weixun
title: The role of SARS‐CoV‐2 target ACE2 in cardiovascular diseases
date: 2021-01-14
journal: J Cell Mol Med
DOI: 10.1111/jcmm.16239
sha: f42876aff99d93b8675d628c4c7ff41cf2a6cd43
doc_id: 779622
cord_uid: 9iez9uwv

SARS‐CoV‐2, the virus responsible for the global coronavirus disease (COVID‐19) pandemic, attacks multiple organs of the human body by binding to angiotensin‐converting enzyme 2 (ACE2) to enter cells. More than 20 million people have already been infected by the virus. ACE2 is not only a functional receptor of COVID‐19 but also an important endogenous antagonist of the renin‐angiotensin system (RAS). A large number of studies have shown that ACE2 can reverse myocardial injury in various cardiovascular diseases (CVDs) as well as is exert anti‐inflammatory, antioxidant, anti‐apoptotic and anticardiomyocyte fibrosis effects by regulating transforming growth factor beta, mitogen‐activated protein kinases, calcium ions in cells and other major pathways. The ACE2/angiotensin‐(1‐7)/Mas receptor axis plays a decisive role in the cardiovascular system to combat the negative effects of the ACE/angiotensin II/angiotensin II type 1 receptor axis. However, the underlying mechanism of ACE2 in cardiac protection remains unclear. Some approaches for enhancing ACE2 expression in CVDs have been suggested, which may provide targets for the development of novel clinical therapies. In this review, we aimed to identify and summarize the role of ACE2 in CVDs.

damage ( Figure 1 ). 6, 7 Because of the distribution and the function of ACE2, it must play a decisive role in COVID-19 patients with multiple organ damage.

ACE2 was first discovered in 2000 by Donoghue and Tipnis. 8, 9 The human ACE2 gene is 40 kb long, located on chromosome Xp22 and composed of 18 exons. 8, 9 The protein of human ACE2, which is a type I integral membrane glycoprotein with an N-terminal signal peptide region, a hydrophobic region near the C terminus and a single active site catalytic region, is approximately 120 kD and consists of 805 amino acids. 9 ACE2 has 42% homology with the amino acid sequence of ACE and is widely expressed in the body, including the heart, vasculature, kidneys, testes, gastrointestinal tract, brain and lungs. [10] [11] [12] Moreover, ACE2 is not only a plasma membrane-bound ectoenzyme; its soluble active form exists in plasma and urine, and it can be detected via routine blood tests. 13 In the heart, ACE2 is mainly expressed in cardiomyocytes, cardiac fibroblasts and coronary artery endothelial cells and also serves as an important endogenous antagonist of the renin-angiotensin system (RAS), which mainly converts angiotensin II (Ang II) to angiotensin-(1-7) [Ang-(1-7)] and metabolizes angiotensin I (Ang I) to generate angiotensin-(1-9) [Ang-(1-9)]. Ang-(1-7) and Ang-(1 -9) have been proven to have significant beneficial effects on the cardiovascular system. 9, 14 Ang-(1-7) generally binds to the Mas receptor (MasR), a G protein-coupled receptor discovered in 1986, and further regulates downstream molecular pathways, including the mitogen-activated protein kinase (MAPK), protein kinase B (AKT) and oxidative stress-related pathways. [15] [16] [17] [18] ACE2 restrains Ang II accumulation and down-regulates the angiotensin II type 1 receptor (AT1R), such that the ACE2/Ang-(1-7)/MasR axis has the opposite effect of the ACE/Ang II/AT1R axis and promotes anticardiovascular remodelling and mediate vasodilation. 19 In addition, angiotensin II type 2 receptor (AT2R), one of the core receptors of the angiotensin family, is also activated by Ang-(1-7). 20 ACE2/Ang-(1-7)/AT2R axis has the same beneficial effects as ACE2/Ang-(1-7)/MasR axis; however, the researches about the axis are limited. 21 Given the existing knowledge of ACE2 distribution and function in the heart, we hypothesized that ACE2 plays a crucial role in the progression of SARS-CoV-2-induced myocardial injury. The present review aims to identify and summarize the functions and mechanisms of ACE2 in clinical and animal models of major CVDs.

Due to the high expression of ACE2 in the heart and the mechanism of SARS-CoV-2 transfection, we speculate that the poor prognosis of COVID-19 patients may be correlated with heart injury. At present, there are two major hypotheses about SARS-CoV-2-mediated damage to the heart. On the one hand, SARS-CoV-2 directly causes heart injury in patients without any CVDs; on the other hand, SARS-CoV-2 can also contribute to the negative prognoses of patients with heart diseases. 22, 23 In addition, some severe COVID-19 patients display higher levels of cardiac troponin I (cTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and creatine kinase-MB (CK-MB), which collectively demonstrates that SARS-CoV-2 aggravates heart injury. [24] [25] [26] [27] A meta-analysis of cTnI in COVID-19 patients including four studies exhibited that the standardized mean difference (SMD) of cTnI was 25.6 ng/L. 26 In addition, a multi-centre cohort study involving 191 patients infected with SARS-CoV-2 showed that of the 54 deceased patients, 48% had hypertension, 24% had coronary heart disease, and approximately 23% had heart failure (HF). 28 Based on the clinical phenomena of ACE2 and heart injury, several studies have suggested that SARS-CoV-2 binds to ACE2 to enter cells and increases the expression levels of disintegrin and metalloproteinase 17 (ADAM17), which, in turn, induce ACE2 shedding.

Thus, the function of ACE2 is compromised and simultaneously F I G U R E 1 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binds to angiotensin-converting enzyme 2 (ACE2) and induces ACE2 shedding to produce soluble ACE2 in serum, which triggers an angiotensin II (Ang II)-mediated inflammation response accompanied by increasing ACE and Ang II expression levels. A higher level of Ang II not only has severe negative effects on the heart, but also increases cytokine release, including interleukin (IL)-6 and IL-7, which activate the MAPK pathway and thereby increase ADAM17 expression to form a positive feedback loop.

Thus, ACE2 appears to be a major regulating factor in COVID-19 patients. [29] [30] [31] In recent years, an increasing number of studies have confirmed that neither ACE inhibitors (ACEIs) nor Ang II receptor blockers (ARBs) are associated with high mortality, which suggests that ACEIs and ARBs cannot exacerbate the prognoses of COVID-19 patients. Meanwhile, there has been no evidence to support that evaluating ACE2 expression can improve heart injury during SARS-CoV-2 infection. [32] [33] [34] In addition, although some drugs, like remdesivir, lopinavir and dexamethasone, have been identified to improve COVID-19 patients' symptoms and attenuate inflammatory response, there are no specific drugs invented to treat cardiovascular injury caused by SARS-CoV-2. [35] [36] [37] Based on the aforementioned information, we believe that the most powerful approach of addressing SARS-CoV-2-induced heart injury is to clarify the upstream and downstream molecular pathways of ACE2 in CVDs and find effective strategies to protect the heart.

MI has a high incidence among patients with CVDs, and in the United States, nearly 0.8 million people are reported to suffer from MI each year. 38 In recent years, multiple studies have shown that the RAS, especially ACE2, is involved in MI-induced myocardial remodelling. 39 In the early stage of MI, both ACE2 and ACE levels are remarkably increased in the heart, whereas in the late stage, ACE2 expression declines and is accompanied by HF, indicating the role of ACE2 against the RAS. 40, 41 Similarly, clinical research has found that the serum ACE2 level of MI patients is significantly higher than that of healthy individuals and results in a negative prognosis. 42 44 In contrast, overexpression of ACE2 can reverse collagen deposition by inhibiting the transforming growth factor-β (TGF-β) pathway with decreasing collagen Ⅰ and Ⅲ

, which also reduces the expression levels of inflammation-related factors ACE and Ang Ⅱ. [45] [46] [47] Diminazene (DIZE), an activator of ACE2, is also used in some studies to improve myocardial function following MI. Chen et al illustrated that DIZE attenuated MI in rats via a novel signalling pathway mediated by ACE2/AT1R/MasR. 48 Given these findings, ACE2 may also be a therapeutic target for MI; however, as no effective drugs can adequately evaluate ACE2 expression in the heart, the concrete molecular mechanisms underlying ACE2 actions need to be further investigated.

Hypertension is one of the most common CVDs that is characterized by vascular remodelling and endothelial injury and leads to severe prognosis. RAS is a participant in the development of the disease. 49 It is known that the ACE/Ang Ⅱ/AT1R axis regulates the constriction of blood vessels, and most available drugs aim to block this pathway. The ACE2/Ang-(1-7)/MasR axis is a potential target for combating the negative effects of the ACE/Ang Ⅱ/AT1R axis on hypertension, and ACE2 plays a key role in this axis. ACE2 regulates blood pressure under physiological conditions, and downregulation of ACE2 gene leads to significant increase in the blood pressure along with an excess accumulation of Ang Ⅱ. 50 In addition, ACE2 is significantly decreased in spontaneously hypertensive rat (SHR) or Ang Ⅱ-induced hypertension models. 51, 52 Interestingly, ACE2 and Ang Ⅱ can regulate each other to maintain a balance.

Ang Ⅱ up-regulates AT1R and increases ADAM17 expression, which causes ACE2 shedding and diminishes the protective impact of ACE2 in hypertension whereas Ang Ⅱ can be converted into Ang-(1-7) by ACE2 to inhibit its own negative effect. 53 61 Although the role of ACE2 in hypertension is clear, the underlying mechanism needs to be elucidated to identify the relevant downstream signalling pathways and clinical trials need to be designed to determine whether up-regulating the ACE2 level can lower blood pressure in patients.

Arrhythmia is myocardial disease that is caused by electrophysiological dysfunction and is often associated with oxidative stress. 62 The RAS has been proven to be involved in the development of arrhythmia. 63 As a significant protein in the RAS, ACE2 exerts negative effects on arrhythmia during the early stage. In 65 These findings resulted from decreases in atrial fibrosis collagen protein markers and TGF-β, which may be one of the molecular mechanisms underlying the protective effect of ACE2 in atrial fibrillation. 66 In addition, strong evidence has shown that ACE2 agonist DIZE can reverse hyperglycaemia-induced cardiac electrical changes in ventricular repolarization, thereby shortening the QT and QTc intervals on an electrocardiogram. 67 Moreover, Ang-(1-7) is a crucial protein in the downstream regulation of ACE2 that also plays a role in antiarrhythmic effects via reducing action potential repolarization phases and decreasing the late sodium (Na + ), L-type Ca 2+ and Na + -Ca 2+ exchanger currents, thereby further mediating the balance of intracellular Ca 2+ and sarcoplasmic reticulum Ca 2+ . 68, 69 Therefore, additional emphasis should be placed on the role of ACE2 in arrhythmia, and new strategies for clinical antiarrhythmic drugs should be developed.

Metabolic dysfunction is a major consequence of diabetes and includes oxidative stress, inflammation and multiple organ injuries in the later stage, especially to the heart. The specific pathogenesis is thought to be related to the RAS. 70 Recent studies have shown that the ACE2/Ang-(1-7)/MasR axis plays a significant role in diabetesinduced cardiomyopathy. The expression of ACE2 decreased in the myocardial tissue of diabetic rats; furthermore, it inhibited myocardial collagen expression as well as promoted collagen degradation by regulating the TGF-β pathway and activating MMP2. 71 Interestingly, ACE2 also exerts this role by regulating Ang-(1-7) and Ang-(1-9) before activating angiotensin II type 2 receptor (AT2R). [72] [73] [74] 

HF is a terminal stage of heart injury caused by various factors and characterized by systolic dysfunction. Besides of the above diseases, dilated cardiomyopathy, age-related myocardial damage and cardiac afterload pressure overload all can induce HF happening. No clinically effective treatment strategies or sensitive predictive indicators exist to provide an early warning of the disease. 82 As ACE2 was discovered, an increasing number of studies have prioritized identifying a novel therapeutic breakthrough based on the ACE2 pathways. Some reports have focused on the serum level of ACE2 in HF patients, which revealed that serum ACE2 is increased in HF and indicated that ACE2 has the potential to become a reliable marker with the same efficacy as BNP. 83 Eplerenone also appeared to attenuate NADPH oxidation, leading to the same effect as spironolactone in macrophages treated with aldosterone. 90 B38-CAP, discovered from Paenibacillus sp, has a structure similar to ACE2 and significantly improves pressure overload-induced HF and cardiac hypertrophy. 91 Notably, recombinant human ACE2 (rhACE2) is also widely used in basic and clinical research for converting Ang Ⅱ to Ang-(1-7) against dilated cardiomyopathy in HF patients. RhACE2 has also been observed to attenuate doxorubicin-induced cardiac dysfunction by protecting cardiomyocyte autophagy. 92, 93 However, despite the increasing number of studies that have focused on the therapeutic role of ACE2 for patients with HF, specific target drugs need to be developed.

A significant amount of data has shown that ACE2 plays a crucial role in countering the development and progression of CVDs.

In addition, the ACE2/Ang-(1-7)/MasR axis can improve CVDs through vasodilation, antiventricular remodelling, anti-inflammatory, antioxidant and antimyocardial fibrosis effects. Studies on the other signalling pathways of ACE2 are scarce, and only a handful of classic pathways have been explored in CVDs. In hypertension, the function of ACE2 is to vasodilate and reduces blood pressure primarily by antagonizing the ACE/Ang II/AT1R axis, which can also affect the NO signal pathway in the CNS. In arrhythmias, ACE2 activity can reduce the occurrence of arrhythmic events and regulate calcium-iron discrepancies. In addition, the antidiabetic cardiomyopathy effect of ACE2 is closely related to its antifibrosis effect via regulation of the TGF-β signalling pathway. stage, but which needs further long-term clinical experiments. As the receptor for SARS-CoV-2, ACE2 has become a major concern in recent months, and related investigations have shown that it is significantly related to the virulence and severity of the virus. Due to its high expression in the heart tissue as well as clinical studies that have identified widespread myocardial injury in infected patients, understanding the pathophysiological role of ACE2 in the heart is of the utmost importance. As a result, ACE2 is regarded as a potential target for the treatment of COVID-19 infection. In the feature, we believe the best methods defending against cardiovascular injury induced by SARS-CoV2 infection are to focus on vaccine development and medicines targeting ACE2. Thus, identifying mechanisms to inhibit the ACE2 binding site for SARS-CoV-2 without harming its normal physiological function in the heart presents a new challenge for researchers in the midst of the current global pandemic.

The authors declare that there are no conflicts of interest. 

https://orcid.org/0000-0002-4987-1339

Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system

Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II

Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

Angiotensin (1-7) prevents angiotensin II-induced nociceptive behaviour via inhibition of p38 MAPK phosphorylation mediated through spinal Mas receptors in mice

Angiotensin 1-7 ameliorates 6-hydroxydopamine lesions in hemiparkinsonian rats through activation of MAS receptor/PI3K/Akt/BDNF pathway and inhibition of angiotensin II type-1 receptor/NF-κB axis

Olmesartan inhibits cardiac hypertrophy in mice overexpressing renin independently of blood pressure: Its beneficial effects on ACE2/Ang(1-7)/Mas axis and NADPH oxidase expression

Role of ACE2 in diastolic and systolic heart failure

AT₂ receptor activation induces natriuresis and lowers blood pressure

ROS and endothelial nitric oxide synthase (eNOS)-dependent trafficking of angiotensin II type 2 receptor begets neuronal NOS in cardiac myocytes

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Cardiovascular implications of fatal outcomes of patients with coronavirus disease

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical Characteristics of 138 Hospitalized Patients With 2019 novel coronavirus-infected pneumonia in Wuhan

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

p38 MAPK inhibition: A promising therapeutic approach for COVID-19

COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease

Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19

Cardiovascular disease, drug therapy, and mortality in COVID-19

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers

COVID-19: Discovery, diagnostics and drug development

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Heart disease and stroke statistics-2019 update: A report from the American heart association

The ACE2-Ang (1-7)-Mas receptor axis attenuates cardiac remodeling and fibrosis in post-myocardial infarction

Myocardial infarction increases ACE2 expression in rat and humans

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: A prospective controlled study

Association between serum angiotensin-converting enzyme 2 levels and postoperative myocardial infarction following coronary artery bypass grafting

Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction

ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction

Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology

ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts

Protective effect of diminazene attenuates myocardial infarction in rats via increased inflammation and ACE2 activity

ESC/ESH Guidelines for the management of arterial hypertension

Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice

Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension

Clinical relevance and role of neuronal AT receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension

Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function

Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models

Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension

Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/ Angiotensin-(1-7) axis in mice

AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension

Angiotensin-converting enzyme 2: a new target for neurogenic hypertension

Role of oxidative stress in the genesis of ventricular arrhythmias

ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications

Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins

Atrial overexpression of angiotensin-converting enzyme 2 improves the canine rapid atrial pacing-induced structural and electrical remodeling. Fan, ACE2 improves atrial substrate remodeling

Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Activation of angiotensin-converting enzyme 2 improves cardiac electrical changes in ventricular repolarization in streptozotocin-induced hyperglycaemic rats

New insights into the elucidation of angiotensin-(1-7) in vivo antiarrhythmic effects and its related cellular mechanisms

Angiotensin 1-7 modulates electrophysiological characteristics and calcium homoeostasis in pulmonary veins cardiomyocytes via MAS/PI3K/eNOS signalling pathway

Contribution of Impaired Insulin Signaling to the Pathogenesis of Diabetic Cardiomyopathy

Angiotensin-converting enzyme-2 overexpression improves left ventricular remodeling and function in a rat model of diabetic cardiomyopathy

Combination of angiotensin-(1-7) with perindopril is better than single therapy in ameliorating diabetic cardiomyopathy

Angiotensin-(1-7) treatment mitigates right ventricular fibrosis as a distinctive feature of diabetic cardiomyopathy

Treatment with angiotensin-(1-9) alleviates the cardiomyopathy in streptozotocin-induced diabetic rats

Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/ db mice by reducing lipotoxicity and inflammation

Beneficial effects of angiotensin (1-7) in diabetic rats with cardiomyopathy

Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes

Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade

The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts

Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy

Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy

Heart failure can affect everyone: the ESC Geoffrey Rose lecture

Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system

Recombinant Human ACE2 and the Angiotensin 1-7 Axis as Potential New Therapies for Heart Failure

Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP

Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit

Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice

Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice

The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice

Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients

B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction

Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure

MiRNA-30e mediated cardioprotection of ACE2 in rats with Doxorubicin-induced heart failure through inhibiting cardiomyocytes autophagy

The role of SARS-CoV-2 target ACE2 in cardiovascular diseases